Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Shanghai Henlius and Organon’s pertuzumab biosimilar met phase 3 trial goals, and the FDA accepted an application for their denosumab biosimilar; Meitheal Pharmaceuticals expanded its US biosimilars lineup; Celltrion USA’s analysis of Zymfentra (subcutaneous infliximab) showed comparable efficacy and safety between monotherapy and combination therapy for inflammatory bowel disease, supporting monotherapy as a viable option.
Shanghai Henlius Biotech and Organon Updates
Partners Shanghai Henlius Biotech and Organon announced that the phase 3 clinical trial for the investigational biosimilar HLX11, a pertuzumab biosimilar, met its primary end point.1
Henlius granted Organon global commercialization rights (excluding China) for HLX11 under a 2022 license and supply agreement. The trial (NCT05346224) compared HLX11 with Perjeta as a neoadjuvant therapy for HER2-positive, hormone receptro–negative early or locally advanced breast cancer, alongside trastuzumab and docetaxel.
Patients received treatment every 3 weeks for 4 cycles, and the primary end point—total pathological complete response rate—was achieved. Secondary end points, including safety and pharmacokinetics, are still being analyzed. Pertuzumab is already approved for use with trastuzumab and chemotherapy in various regions for treating advanced HER2-positive breast cancer.
Additionally, the companies announced that the FDA accepted the biologic license application for HLX14, a biosimilar to denosumab (Prolia/Xgeva), used to treat osteoporosis in postmenopausal women at high risk for fractures.2
Under the aforementioned 2022 agreement, Organon holds exclusive commercialization rights for HLX14 in the US, European Union (EU), and Canada. The application is supported by extensive studies: a phase 1 study in Chinese male subjects to establish pharmacokinetic similarities and a global phase 3 trial demonstrating HLX14's efficacy, safety, and immunogenicity compared to EU-sourced Prolia in postmenopausal women with osteoporosis.
Meitheal Signs Deal for US Biosimilars
Meitheal Pharmaceuticals has expanded its biosimilars portfolio through an exclusive licensing agreement with its parent company, Hong Kong King-Friend Industry.3 This agreement grants Meitheal the rights to market and distribute 3 biosimilars in the US: a pegfilgrastim, a filgrastim, and a follitropin alpha.
The first 2 are oncology medications for supporting white blood cell production during cancer treatment to prevent febrile neutropenia. Follitropin alpha, a recombinant form of human follicle-stimulating hormone (FSH), addresses a significant unmet need in the US fertility market, which saw $847 million in branded FSH sales in 2023. With no existing biosimilar alternatives for follitropin alpha, the product offers an affordable option for fertility patients.
Meitheal’s parent company has invested over $300 million to bolster product supply and research, including $30 million in a monoclonal antibody facility. With these additions, Meitheal’s biosimilars portfolio now totals 8 treatments.
Zymfentra Data Through 102 Weeks
Celltrion USA presented a post hoc analysis of the LIBERTY-CD and LIBERTY-UC studies for Zymfentra (infliximab-dyyb), the world’s first subcutaneous infliximab product, at the 2024 American College of Gastroenterology Annual Meeting.4
This analysis found comparable clinical outcomes for patients with inflammatory bowel disease (IBD) treated with Zymfentra as monotherapy versus combination therapy with immunosuppressants, indicating that monotherapy may be a viable option. Zymfentra, the only FDA-approved subcutaneous infliximab, had previously shown significant efficacy over placebo for maintenance in IBD.
The analysis included 429 patients with IBD and showed similar efficacy and safety profiles between monotherapy and combination therapy up to Week 102, though combination therapy generally resulted in higher mean infliximab levels.
Results showed that monotherapy achieved similar clinical outcomes to combination therapy at weeks 54 and 102, suggesting it could be an effective option without the added immunosuppressant. While combination therapy generally had higher infliximab trough levels after week 10, both approaches demonstrated comparable safety profiles, highlighting Zymfentra monotherapy as a potential choice for IBD patients aiming to minimize medication burden.
"The new data strengthens the case for Zymfentra monotherapy as a potential treatment option for patients with Crohn's disease and ulcerative colitis," said Hetal Patel, PharmD MBA, head of medical affairs at Celltrion USA. “These findings suggest that Zymfentra could offer flexibility in treatment approaches, providing confidence in monotherapy as an alternative to combination therapy, while maintaining effective disease control."
References
1. Primary endpoint met in phase 3 comparative clinical study of Perjeta (pertuzumab) biosimilar candidate HLX11. Organon. News release; September 30, 2024. Accessed November 4, 2024. https://www.organon.com/news/primary-endpoint-met-in-phase-3-comparative-clinical-study-of-perjeta-pertuzumab-biosimilar-candidate-hlx11/
2. US fda accepts biologics license application (BLA) for HLX14, biosimilar candidate of Prolia/Xgeva (denosumab). Organon. News release; October 30, 2024. Accessed November 4, 2024. https://www.organon.com/news/us-fda-accepts-biologics-license-application-bla-for-hlx14-biosimilar-candidate-of-prolia-xgeva-denosumab/
3. Meitheal Pharmaceuticals secures exclusive commercial licensing agreement for three biosimilars in the U.S. Meitheal Pharmaceuticals. News release; October 31, 2024. Accessed November 4, 2024. https://www.meithealpharma.com/news/90
4. Celltrion presents post hoc analysis of LIBERTY studies of Zymfentra (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting. Celltrion USA. News release; October 30, 2024. Accessed November 4, 2024. https://en.prnasia.com/releases/global/celltrion-presents-post-hoc-analysis-of-liberty-studies-of-zymfentra-infliximab-dyyb-at-the-american-college-of-gastroenterology-2024-annual-scientific-meeting-466440.shtml
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.